. The large outer loop -called the large extracellular loop (LEL) or extracellular domain 2 (EC2) -can be further divided into a constant region, containing conserved A, B and E helices, and a variable region containing sites for specific protein-protein interactions 3, 4, 7 . Structural data from uroplakin tetraspanins (UPK1A, UPK1B) 8 and from molecular models of tetra spanins 9, 10 indicate close packing of the four transmembrane domain helices and an overall rod-shaped structure (FIG. 1b) , which is suitable for the docking of partner proteins 8 .
In support of this model, tetraspanin extracellular domains, transmembrane domains [11] [12] [13] and intracellular membrane-proximal cysteines 14 can all be in close contact with neighbouring proteins. Other similarly sized proteins also contain four transmembrane domains; for example, the L6 family proteins, the connexins and the PMP22/EMP/MP20/Claudin superfamily of proteins. Although these other proteins may be tetraspans, they are not members of the tetraspanin family because they lack sequence homology and key structural features of tetraspanins.
At least a few different tetraspanins are expressed on nearly all cell and tissue types 1 . Details regarding human tetraspanin expression on specific normal and malignant cell and tissue types can be found at Oncomine Research (see Further Information) and elsewhere [15] [16] [17] . Genetic evidence in a number of species, including fungi, worms, flies, mice and humans, confirms that tetraspanins exert a wide-ranging influence on the nervous system, immune system, tumours, infectious disease processes, fertilization, and development in skin and other organ systems [18] [19] [20] [21] [22] [23] . Besides determining cell morphology, tetraspanins also modulate cell motility, invasion, fusion, adhesion strengthening, signalling and protein trafficking 5, 17, 19 . This Review will discuss the functions of specific tetraspanins, their key molecular interactions and their prospects as therapeutic targets.
Tetraspanin microdomains
Tetraspanins protrude only 4-5 nm from the plasma membrane 7, 8 . They do not typically serve as cell-surface receptors, although the hepatitis C virus protein E2 can bind to CD81 (ReF. 24) , the FimH protein in uropathogenic bacteria binds to tetraspanin UPK1A 25 , and ligands for tetraspanin CD9 have been suggested 26 . Tetraspanins are best known for their ability to organize laterally into tetraspanin-enriched microdomains (TEMs). Initially, TEMs were defined biochemically based on the tendency of tetraspanin proteins and their partners to remain associated under non-stringent detergent conditions 23, 27 . Later, they were characterized by immunoelectron microscopy as units, with an area of ~0.2 mm 2 and 0.6-0.7 mm spacing, sometimes appearing on the plasma membrane 28 . The presence of gangliosides and cholesterol 27, 29, 30 helps to explain the resistance of TEMs to solubilization 
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Integrins A family of cell-surface transmembrane proteins (24 mammalian members), with αb-heterodimeric structures, which function as cell adhesion molecules.
EWI proteins
A family of four cell-surface immunoglobulin superfamily proteins, sharing a conserved glutamine-tryptophanisoleucine (eWI) motif.
Protein palmitoylation
Post-translational acylation of a protein, typically on an intracellular cysteine residue.
Exosomes
Vesicles of 50-100 nm, enriched 10-fold to 100-fold for tetraspanins, and shed from the multivesicular bodies of cells.
Monoclonal antibody
A specific antibody produced in large quantity by a single hybrid cell clone formed in the laboratory by the fusion of a B cell with a tumour cell.
with detergent, while suggesting similarity to lipid rafts 19 . However, evidence involving cholesterol depletion, detergent solubilization, sucrose density analyses and palmitoylation-site mutation 19, 23, [31] [32] [33] [34] [35] [36] clearly establishes TEMs as discrete biochemical entities, which is in contrast to the rather ambiguously defined lipid rafts.
At the core of TEMs are tetraspanins engaging in direct protein-protein interactions with both transmembrane and intracellular proteins, including the immunoglobulin superfamily members EwI-2 (also known as IGSF8, CD316) and EwI-F (also known as C9P-1, FPRP), Claudin 1, epidermal growth factor receptor (EGFR) membrane-bound ligands, integrins and Syntenin-1, to carry out various functions (Box 1). These primary complexes include tetraspanin homodimers, which have been captured by covalent crosslinking 37 and by protein crystalli zation 7 . Tetraspanins also form primary complexes with several other types of molecules (TABle 1) .
Primary complexes then join into a network of looser secondary interactions, which include not only multiple distinct tetraspanins, and many other transmembrane proteins 19, 38 , but also signalling enzymes such as conventional protein kinase C (PKC) isoforms 39, 40 and phosphatidylinositol 4-kinase 41, 42 . Of the more than 100 tetraspanin partners that have been identified, most of them fall into the category of 'secondary' interacting partners, mainly because direct association has not been demonstrated and/or because association is lost under more stringent detergent conditions such as 1% Triton X-100 and digitonin, as compared with resistance to milder detergents such as 1% Brij 96 and 1% Brij 99 (ReF. 19 ).
Notably, tetraspanins and many of their partner proteins (such as integrins, eWI proteins and Claudin-1) undergo protein palmitoylation, which does not contribute to primary interactions but helps to stabilize secondary interactions within TEMs [32] [33] [34] . Among the 8 b and 18 α subunits that comprise the integrin family, the only subunits that undergo palmitoylation are α 3 , α 6 , α 7 and b 4 . Interestingly, it is these same subunits that form the most robust associations with tetraspanins. A practical consequence of the enrichment for palmitoylated proteins within TEMs is that metabolic labelling with 3 H-palmitate is a particularly useful tool for studying TEMs [43] [44] [45] . Cholesterol can physically and functionally associate with TEMs 30, 46 . Treatment of cells with methyl-b-cyclodextrin to deplete cholesterol reduces CD81 oligomerization 46 , and with more extensive treatment intact TEMs can be released into the media in microvesicles 14, 31 . In a natural process that may be related, multi vesicular bodies assemble and are then shed to form 50-100 nm vesicles, known as exosomes 47 . It remains to be determined whether tetraspanins have a functional role in the production or maintenance of exosomes or other types of microvesicles. In one instance, exosomes have been shown to deliver a pro-angiogenic stimulatory signal that was dependent on the presence of the tetraspanin TSPAN8 (previously known as CO-029, TM4SF3) 48 , emphasizing that exosome tetraspanins can be functionally active.
Targeting tetraspanin-dependent functions So far, there has been negligible drug discovery targeting of tetraspanins, perhaps because cell-surface tetraspanins do not typically interact with soluble ligands or counter-receptors on apposing cells. In addition, many of the 33 mammalian tetraspanins have been only minimally studied. However, as more reagents are generated (such as monoclonal antibodies (mAbs), small interfering RNAs (siRNAs) and transgenic mouse models) and new assay systems become available, further examples of tetraspanins as potential therapeutic targets should emerge. Nonetheless, several tetraspanins have already been implicated in a number of normal and pathological processes with the potential to be targeted therapeutically (TABle 2) .
Normal physiology and non-infectious diseases Tumour progression. Tetraspanin CD151 may contri bute to tumour progression at multiple levels. For example, CD151 expression is significantly increased in prostate cancer compared with benign prostate hyperplasia 49 . Moreover, higher levels of CD151 are associated with poor prognosis in lung and prostate cancers 49, 50 , and overexpression of CD151 promotes metastasis in colon carcinoma and fibrosarcoma cells 51 . In addition, CD151 expression is increased in a subset of human breast cancer samples, particularly those of high grade and/ or triple negative basal-type 45 . Consistent with CD151 having a functional role in cancer development, its ablation from basal-like breast cancer cells impairs both ectopic and orthotopic growth in xenograft models 45 . The mechanistic consequences of CD151 ablation include subcellular redistribution of α 6 integrins, Figure 1 | Tetraspanin structural features. a | Shown in this 'unfolded' tetraspanin are membrane-proximal palmitoylations (red), hydrophilic residues within transmembrane domains (grey balls), and extracellular loops (EC1 and EC2). EC2, also called large extracellular loop (LEL) is divided into a constant region, containing A, B and E helices, and a variable region, containing the signature tetraspanin CCG motif, two conserved disulphide bonds (red) and a third loop and disulphide bond (dashed) that appears in some tetraspanins. b | This more realistic scheme emphasizes the close packing of the four transmembrane domains, the proximity of EC1 and EC2, and the overall rod shaped structure of tetraspanins. Disulphide bonds are not shown. This scheme is based on structural results seen for uroplakin tetraspanins UPK1A and UPK1B 8 , and modelled for other tetraspanins 9, 10 .
Angiogenesis
The process by which new blood vessels grow from pre-existing blood vessels.
reorganization of integrin partner proteins and altered migration and invasion accompanied by diminished adhesion-dependent signalling through the Rho GTPase subfamily member RAC1 and focal adhesion kinase FAK 45 . Interestingly, anti-CD151 antibodies have been shown to inhibit spontaneous and experimental metastasis and tumour cell intravasation, but not tumour growth, in chick embryo and mouse xenograft models, or in epidermoid carcinoma, fibrosarcoma or colon carcinoma cells [51] [52] [53] . Primary tumour growth and metastasis are strongly supported by CD151, not only when it is present on tumour cells but also when present in the host animal. Lewis lung carcinoma cells implanted into CD151-null mice show markedly reduced primary tumour growth 44 through a mechanism that may involve diminished tumour angiogenesis in the host mouse (see below). Furthermore, host CD151 contributes to experimental metastasis. For example, in CD151-null mice, lung melanoma colonies are diminished in number but not in size, suggesting that CD151 affects the initiation of metastatic growth but not proliferation (Y. Takeda et al., personal communication) . In all of these studies, CD151 mostly acts in concert with laminin-binding integrins 44, 45 . There may be an advantage in targeting CD151, rather than the laminin-binding integrins to which it associates, as the α 3 b 1 and α 6 b 4 integrins are needed for normal development of skin and kidney and other tissues in 129Sv and/or C57BL6 mice [54] [55] [56] . By contrast, CD151 is not needed for normal development in those mouse strains 44, 57 , although it can affect kidney function when mice are at least partly bred into the FvB mouse strain 58 , and it may contribute to normal human kidney and skin development 59 . It remains to be seen whether CD151 targeting can ablate tumour progression without adversely affecting normal physiology.
Apart from CD151, the tetraspanin TSPAN8 is also associated with tumour progression. Overexpression of TSPAN8 supports pancreatic adenocarcinoma metastasis 60, 61 , and TSPAN8 is increased on hepatocellular carcinomas that are poorly differentiated and prone to intrahepatic spreading 62 . In addition, TSPAN8 is upregulated in oesophageal carcinoma and promotes invasion and migration in oesophageal carcinoma cell lines 63 .
Tetraspanins may also act as tumour suppressors. For example, the presence of CD9 (ReFs 64-66) impairs invasion, metastasis and/or survival in many cancer cell types. CD9 may also suppress primary growth of colon carcinomas 67 , whereas TSPAN13 (previously known as NET-6, TM4SF13) can suppress breast carcinoma proliferation and invasion in vitro 68 , and CD63 may suppress melanoma growth and metastasis 69 . Although the latter result has been called into question owing to a cell-line contamination 70 , another report shows that knockdown of CD63 elevates the invasive potential of melanoma cells 71 , consistent with CD63 having suppressor function. CD82 (previously known as KAI1) is perhaps the most well-known tetraspanin tumour suppressor 72 . It was initially reported to suppress prostate cancer metastasis 73 . Now, at least 11 different tumour types show an inverse correlation between CD82 expression and tumour invasion and/or metastasis 72 . Tumour suppression activity could be related to CD82-induced redistribution and/or downregulation of other crucial cell-surface molecules including gangliosides and EGFR 74 , urinary plasminogen activator receptor (UPAR) 75 and the α 6 b 1 integrin 76 .
Angiogenesis. CD151-null mice are defective in angiogenesis in vivo, in assays involving implantation of corneal pellets, subcutaneous Matrigel plugs and subcutaneously injected tumour cells 44 . However, vascular development appears normal in these mice 44, 57, 58 , emphasizing that the angiogenesis defect may be restricted to pathological conditions. In support of a pro-angiogenic role for CD151, overexpression of CD151 promotes neovascularization and improves blood perfusion in a rat hindlimb ischaemia model, probably by a mechanism that involves activation of the phosphotidylinositol 3-kinase (PI3K)-AKT signalling pathway 77 . The absence of CD151 does not affect angiogenesis in an in vivo oxygen-induced retinopathy model 44 , perhaps because retinal vascularization depends more on a specialized astrocytic template 78 and less on a typical laminin-containing basement membrane. CD151,
Box 1 | Tetraspanin primary complexes
Tetraspanins are involved in direct protein-protein interactions with both transmembrane and intracellular proteins.
For example, tetraspanins CD9 and CD81 can directly associate with EWI-2 and EWI-F, a pair of related cell-surface proteins in the immunoglobulin superfamily, named for a conserved Glu-Trp-Ile motif. EWI-2 negatively regulates cell motility, morphology and spreading in several cell lines 81, 139, 165 . EWI-2 also impairs orthotopic tumour growth when expressed in a glioblastoma cell line (T. V. Kolesnikova et al., personal communication) . It is doubtful that EWI-2 functions without being associated with CD9 and/or CD81 because CD81 (and possibly also CD9) facilitate the cell-surface expression of EWI-2 (ReF. 81 ). Also, EWI-2 redirects CD81 and CD9 into filopodia 81 and causes CD9 to switch from homo oligomerization to EWI-2 hetero association 141 . A truncated form of EWI-2, called EWI-2wint, associates with CD81 and blocks hepatitis C virus entry 166 . In addition, CD9 directly associates with Claudin-1 when it is not present in tight junctions, leading to prolonged Claudin-1 half-life 14 . Other tetraspanins (CD81, CD151) may also associate physically and functionally with Claudin-1 (ReFs 14,115), but it is not yet clear whether these associations are direct. Also, CD9 can associate with heparin-binding epidermal growth factor-like growth factor (HB-EGF), and other membrane-bound ligands for the epidermal growth factor receptor (EGFR), to promote juxtacrine signalling [167] [168] [169] . Furthermore, CD9 can modulate proteolytic release of soluble EGFR agonists, leading to either suppression 169 or stimulation 170 of paracrine signalling. Tetraspanin CD81 associates with and facilitates the biosynthesis of CD19 (ReF. 89 ), a molecule that plays a pivotal role during signalling through the B-cell receptor 171 . CD81 also associates closely with the integrin α 4 b 1 (ReF. 138) , and regulates α 4 b 1 adhesion strengthening under shear flow conditions 90 . Tetraspanin CD151 associates directly with laminin-binding integrins (
, with association occurring early in biosynthesis. Indeed, CD151 associates with the integrin α 3 subunit in the endoplasmic reticulum, even before α 3 -b 1 association 11, 12 . CD151 contributes to laminin-binding integrin-dependent adhesion strengthening, cell spreading, motility and morphology 11, 23, 32, [173] [174] [175] [176] .
Tetraspanins not only associate directly with other transmembrane proteins, but also with intracellular proteins. For example, the C-terminal cytoplasmic tail of tetraspanin CD63 associates directly with a PDZ motif in Syntenin-1, leading to a negative regulation of CD63 endocytosis 157 . It remains to be determined whether PDZ-binding motifs in the C termini of several other tetraspanins will also bind to proteins containing PDZ domains.
which is abundant at endothelial cell-cell junctions, supports several in vitro endothelial cell functions that are of relevance to angiogenesis. These include endothelial cell invasion, chemotactic migration, cable formation, Matrigel contraction, tube formation, sprouting, and signalling through AKT and RAC1 44 . Another tetraspanin, TSPAN8, has also been linked to angiogenesis. when TSPAN8 is expressed on a rat carcinoma cell line, it stimulates angiogenesis in vivo, with TSPAN8 itself also becoming upregulated on newly sprouting endothelium 48 .
Oocyte fertilization. when CD9 and CD81 are absent from oocytes, sperm-egg fusion is completely eliminated 79 . Tetraspanin absence does not affect the initial sperm binding but prevents subsequent sperm-egg fusion events 79 . Oocyte CD9 appears to function by optimizing the length, thickness, density and radius of curvature for oocyte microvilli, which may play an active role in capturing sperm cells 80 . Oocyte CD9 associates closely with its major protein partners (EwI-2 and EwI-F) 80 , which is relevant for two reasons. First, EwI-2 can drive the localization of CD9 and CD81 into filopodia 81 . Second, EwI proteins may associate directly with ezrin-radixin-moesin proteins, thereby linking CD9 and other TEM proteins to the actin cytoskeleton 82 . So, CD9-EwI protein complexes may work together in regulating oocyte microvilli structure and function. During sperm-egg fusion in humans, tetraspanins CD9, CD81 and CD151 may all have a role, with CD9 controlling the molecular organization of key proteins, such as integrin α 6 b 1 , on the oocyte surface 83 . with respect to inhibiting fertilization, tetraspanins may be the most attractive targets yet described 84 . Indeed, multiple strategies have already been used to target oocyte tetraspanins and to inhibit fertilization (see below).
Immune cell functions. Leukocyte subsets -T and B lymphocytes, granulocytes, monocytes, macrophages, dendritic cells and natural killer cells -each express eight or more different tetraspanins 15 . These tetraspanins associate directly or indirectly with numerous molecules -for example, T-cell receptors, B-cell receptors, major histocompatibility complex (MHC) class I, MHC class II, CD2, CD4, CD8, CD19, EwI-2, α 4 b 1 and α 6 b 1 integrins -that have crucial roles in the functions of immune cells 38 . Excellent reviews highlight the extensive and sometimes apparently conflicting roles played by tetraspanins on immune cells 15, 18, 38 . Because of these conflicting roles, and because of the unpredictability of targeting immune cells in general, it is not yet clear whether tetraspanin targeting on immune cells will be a productive endeavour. Nonetheless, a brief overview of some possibilities are discussed.
Antibody crosslinking of several tetraspanins (for example, CD9, CD53, CD81 and CD82) can co-stimulate T cells, suggesting positive effector roles 38 . However, mouse knockout models of four different tetraspanins (CD81, CD37, TSPAN32 and CD151) exhibit T-cell hyperproliferation in response to in vitro stimulation, which is consistent with endogenous tetraspanins exerting negative regulatory functions 57, [85] [86] [87] . These tetraspanins may down-modulate T-cell triggering, either by recruitment of a negative regulatory phosphatase 88 or by sequestering key molecules into TEMs.
On B cells, tetraspanin CD81 is required for molecu lar organization and efficient collaboration between the B cell receptor and its partners (CD21, CD19 and various signalling enzymes) 18 . Also, CD81 is required for maturation and surface expression of CD19 89 , a molecule with a key role during B-cell activation. In addition, CD81 associates with the α 4 b 1 integrin on B cells, thereby strengthening α 4 b 1 integrin adhesion under shear flow conditions 90 . Other tetraspanins also have key roles on B cells. For example, CD9 suppresses the motility of intraperitoneal B1 cells 91 , and CD37 supports T-cell dependent B-cell responses, especially at sub optimal doses of antigen 86 . Tetraspanins may also contribute to antigen presentation. There is extensive evidence for tetraspanin associations with MHC class I and MHC class II molecules 18, 38 , whereas CD81 (on T cells and antigen presenting cells) and CD82 (on T cells) both distribute into immune synapses 92, 93 . Furthermore, multiple tetraspanins associate with a subset of MHC class II molecules that may have distinct antigen presenting properties 35 , and lateral associations between heterologous MHC class II molecules (I-A and I-E) depend on CD9 (ReF. . CD151 functions by physically associating with α IIb b 3 , the major platelet integrin, leading to impaired outside-in (that is, post-ligand occupancy) signalling by the integrin 95 . Another tetraspanin, TSPAN32 (previously known as TSSC6, PHEMX), also associates with α IIb b 3 integrin and modulates outside-in signalling, with TSPAN32-null mouse platelets similarly showing impaired clot retraction, aggregation and spreading on fibrinogen 96 . In addition, TSPAN32 is required for stable platelet thrombus formation during vascular injury 96 . Tetraspanin CD63 also associates with α IIb b 3 integrin and may regulate platelet spreading and signalling on fibrinogen 97 . However, the functions of α IIb b 3 integrins in CD63-null platelets have not yet been evaluated. The α IIb b 3 integrin is a well-established therapeutic target with antagonists widely used to treat coronary thrombosis 98 . It remains to be determined whether integrin-associated tetraspanins, which so far have a less dramatic role, will also be useful targets in platelet thrombus formation.
Several other studies, involving mAbs, suggest additional functional roles for various tetraspanins on platelets and other types of myeloid cells 15 . However, interpretations are complicated by expression of the immunoglobulin-g receptor FcgRIIa and other Fc receptors on myeloid cells, which leads to antibody crosslinking and dual signalling effects 99 . Nonetheless, modulation of Fc receptor signalling by tetraspanins may be relevant to immune disorders 99 .
Other non-infectious disease functions. CD151-null mice show significantly impaired wound healing in a skin incision model, with deficient re-epithelialization being accompanied by laminin basement membrane disorganization and failure to upregulate α 6 and b 4 integrin subunits at the wound site 100 . CD81 has a key role during experimental spinal-cord injury in rats. Intraspinal infusion of an anti-CD81 antibody enhanced motor function, and spared tissue loss at the lesion site 101 . It is suggested that the anti-CD81 antibody inhibits microglial proliferation and/or macrophage recruitment at the injury site 101 . + T cells. Anti-CD9 and anti-CD81 mAbs enhance syncytia formation in T lymphoblasts, apparently by blocking (that is, reversing) the inherent syncytium suppressing effect that is exerted by endogenous T-cell CD9 and CD81 molecules 104 .
Tetraspanins may also have an active role during HIv-1 infection of macrophages. For example, the entry of HIv-1 R5-tropic virus is inhibited by anti-CD63 mAb 105 , and both R5-tropic and X4-tropic viruses can be potently inhibited by soluble LEL/EC2 domains from multiple tetraspanins (CD63, CD81, CD82, CD53 and CD151) 106 . Once inside macrophages, HIv-1 assembles within a novel type of intracellular membrane domain containing CD81, CD9 and CD53, with CD63 then being recruited and incorporated into virions 107 . Finally, HIv-1 egress may occur through TEMs, as key endosomal sorting components (TSG101 and vPS28), involved in HIv-1 budding, are recruited to TEMs upon virus expression 28 . However, it remains to be seen whether specific tetraspanins are required for virus assembly and egress. In this regard, despite CD63 being involved in macrophage infection 105, 106 , and being present at sites of virus assembly and budding 108 , it is not required for virus production in human macrophages 109 . As a consequence of assembly in tetraspanin-enriched compartments, newly released HIv-1 particles show incorporation of CD63 and multiple other tetraspanins. By an unknown mechanism, these embedded tetraspanins have the potential to down-modulate subsequent HIv-1 infection at a post-attachment entry step 110 . (ReFs 14,115), may collaborate with CD81 during a later step in virus entry 115, 116 . Although Claudin-1 is typically found in tight junctions, tetraspanin-claudin complexes are not in tight junctions 14, 117 , which suggests that HCv might engage non-junctional claudins.
Hepatitis C virus. Hepatitis C virus (HCv
Other infectious disease pathologies. Antibodies to CD82 and CD81 block human T-cell lymphotropic virus type 1 (HTLv-1)-induced syncytium formation in T lymphoblastoid cells 118 . Overexpression of CD82 also inhibited syncytium formation, in addition to cell-to-cell virus transmission 119 . . Later studies show that CD9 acts not as a virus receptor, but as a regulator of CDv haemagglutinin-dependent cellcell fusion 122 . These examples of tetraspanins facilitating virus-dependent fusion events are consistent with CD9 and CD81 regulating other types of cell-cell fusion, such as seen for gametes 79 , myoblasts 123 , monocytes during osteoclastogenesis 124 , and monocytes forming multinucleated giant cells 125 . CD9 may also support feline immunodeficiency virus infection. Again, the tetraspanin does not affect virus binding, but instead contributes to virus assembly and/or release 126 . CD81 (but not CD9) is required in hepatocytes to allow invasion by sporozoites from malaria-causing parasites Plasmodium yoelii and Plasmodium falciparum 127 . CD81 functions together with cholesterol in the context of TEMs to enable Plasmodium sporozoite invasion 46 . No interaction between CD81 and sporozoite proteins has been observed, which suggests that CD81 may be playing a co-receptor role 127 . Tetraspanin CD9 is a co-receptor for diphtheria toxin. CD9 does not bind directly to the toxin, but forms a membrane complex with the diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor; HB-EGF), to increase the number of effective binding sites 128 .
Strategies for targeting tetraspanins
Tetraspanins might be targeted using mAbs, recombinant soluble LELs, RNA interference (RNAi) or other approaches (FIG. 2) .
Monoclonal antibodies. As of 2007, over 400 therapeutic mAbs had entered commercially sponsored clinical development 129 . Although this list includes mAbs that target tetraspanin-associated proteins, such as epithelial cell adhesion molecule (EPCAM) and EGFR, mAbs targeting tetraspanins themselves are not listed 129 . However, a few promising in vivo results have so far been observed. For example, mAb targeting of CD81 improves recovery from spinal injury in rats 101 , intrauterine injection of an anti-CD9 mAb increased embryo implantation 130 , intratumour injection of anti-CD9 mAbs inhibited in vivo colon carcinoma growth 67 , and a modified anti-CD37 antibody depleted human B-cell chronic lymphocytic leukaemia (B-CLL) cells and improved survival in a mouse xenograft model 131 . Results listed in effect has not yet been well documented. It is more likely that treatment of cells with multivalent anti-tetraspanin mAbs causes formation of aggregates of TEM proteins, leading to disruption of TEMs and/or down-modulation of the target tetraspanin, perhaps together with key associated proteins. Indeed, it is suggested that the ability of anti-tetraspanin mAbs to perturb large patches of TEM proteins probably explains why mAb treatment effects often exceed the magnitude of effects seen upon knockdown or knockout of individual tetraspanin proteins. For example, anti-CD63 mAb strongly inhibits HIv-1 entry into macrophages 105 , but RNAi ablation of CD63 had no effect on HIv-1 infectivity and virus assembly 109 . Similarly, anti-CD81 antibodies affect numerous cellular functions 132 such as lymphocyte proliferation 133 and thymo cyte development in fetal organ culture 134 , but CD81-null mice show relatively mild phenotypes, with normal lymphocyte proliferation and thymic development 85, 135 . Another mode of action is that the mAb may exert an agonist effect. In this regard, a few anti-tetraspanin antibodies enhance rather than inhibit tetraspanin-dependent functions. For example, an anti-CD151 antibody can stimulate cell adhesion, thereby preventing de-adhesion and immobilizing tumour cells 53 . In other examples, anti-CD9 and anti-CD81 antibodies may stimulate cell-cell fusion, either by an agonist effect or by blocking inherent anti-fusion properties of CD9 and CD81 (ReFs 104,125 ). In addition, anti-CD9 mAbs amplify the inherent tumour suppressor function of CD9 (ReF. 67) .
Despite tetraspanins being relatively small molecules on the cell surface (only ~100 extracellular amino acids), antibodies to the same tetraspanin can have a range of different properties 136 . For example, some anti-CD151 antibodies recognize total protein, whereas others selectively recognize an epitope exposed only when CD151 is not bound to laminin-binding integrins [136] [137] [138] . Similarly, epitopes defined by anti-CD81 and anti-CD9 mAbs vary widely 46, 139, 140 , which is partly due to differential shielding of epitopes. As a practical benefit, specialized anti-tetraspanin mAbs may have utility in diagnosing the molecular state of tetraspanins in intact cells. For example, antibodies that selectively detect unbound CD151 might provide information regarding integrin association [136] [137] [138] , whereas an anti-CD9 antibody might also provide information regarding integrin activation and/or association 140 . A low-affinity mAb that selectively binds clustered CD9 can be used to assess the changes in the state of homo-oligomeric CD9 clustering on the cell surface 141 . Similarly, an antibody with preference for oligomerized CD81 can provide clues regarding the cell-surface organization of CD81 (ReF. 46) .
Besides blocking, clustering or otherwise disrupting specific molecular targets, mAbs also can trigger the removal of target cells. This can be achieved directly by the stimulation of apoptosis in carcinoma cell lines 142 or in myotubes 123 with specific anti-CD81 and/or anti-CD9 antibodies. Alternatively, antibody-coated cells may undergo complement-dependent cytotoxicity (CDC; lysis due to complement fixation) or antibody-dependent cell-mediated cytotoxicity (ADCC). In the latter case, apoptosis is triggered after antibody-coated cells are recognized by Fc receptors of natural killer cells. In this regard, a modified anti-CD37 antibody triggered efficient ADCC-dependent in vivo removal of B-CLL cells 131 . In fact, the therapeutic efficacy of anti-CD37 may surpass that of rituximab (an anti-CD20 antibody) 131 , which is currently used in the treatment of human B-CLL. Finally, mAbs can be coupled to a lethal substance, such as a toxin, radioisotope or nanoparticle, which can then be used to ablate cells bearing the mAb target molecule. Although an iodine [131] -labelled anti-CD37 mAb yielded promising results in patients with B-cell lymphoma 143 , there has been no recent continuation of these studies. It remains to be seen whether other tetraspanins will show the sufficient degree of disease-type, cell-type or tumour specificity needed for this approach.
Soluble EC2 loops. Recombinant soluble LEL/EC2 of tetraspanin CD9 inhibited sperm-egg fusion when preincubated with oocytes but not sperm cells. These results suggest that CD9 may act in cis on the oocyte surface, whereas sperm lack a trans acting counter-receptor for CD9 (ReF. 144) . Subsequent studies confirmed these results using recombinant soluble LELs from CD9 and CD81, with CD63 soluble LEL as a negative control 145 . In other studies, human (but not mouse) CD9 soluble LEL inhibited blood monocyte fusion 125 , and soluble LELs from CD9 and CD151 disrupted endothelial cell interactions with leukocytes 146 . Recombinant soluble LELs have also been used effectively to inhibit virus functions. Multiple soluble LELs (from CD63, CD9, CD81 and CD151) potently inhibit CCR5-tropic HIv-1 infection of macrophages 106 . The soluble LEL proteins appear to act on target cells by interfering with the uptake of virions 106 . In several of these studies, mutant soluble LELs, or soluble LELs from another species, function less effectively, thus serving as important controls. Together, these results, obtained in several different settings, emphasize the utility of soluble LEL reagents. Curiously, HIv-1 infection of macrophages is inhibited by multiple soluble LELs (CD63, CD9, CD81 and CD151) but only by a single anti-tetraspanin mAb (anti-CD63, but not anti-CD9 or anti-CD81). One interpretation of these results is that CD63 plays a more direct role in virus infection, thus explaining mAb selectivity. By contrast, soluble LELs from multiple other tetraspanins may interfere with endogenous lateral homo-tetraspanin and heterotetraspanin oligomerizations, thereby disrupting TEMs, which indirectly impairs the function of CD63.
Recombinant soluble LEL protein from CD81 also inhibits HCv infectivity. In this case, the mechanism is more obvious. During infection, the HCv E2 protein binds directly to cellular CD81, which serves a critical co-receptor function. CD81 soluble LEL binds to the virus E2 protein, thus preventing virus interaction with endogenous CD81 LEL 112 . However, recent work shows that CD81 soluble LEL is minimally effective as an inhibitor in HCv assays that more closely mimic in vivo HCv infection in humans. Although CD81 is still required at an early step in the infection of normal primary human hepatocytes, viral particles appear to be less accessible to inhibitory interaction with CD81 LEL 114 . In summary, soluble LELs from multiple tetraspanins have been used in a number of settings to disrupt tetraspanin-dependent functions. Although the mechanism of action has not been precisely clarified in many of these assays, it is presumed that soluble LELs can disrupt lateral interactions essential for assembly and/or maintenance of TEMs. Hence, by exerting a combination of direct and indirect effects, soluble LELs may offer a broader range of inhibitory possibilities than mAbs. However, in the case of HCv, in which the LEL binds to virus instead of cells, anti-CD81 mAbs may be more potent 114 .
RNAi approaches.
Another strategy for interfering with tetraspanins involves small interfering (siRNA) knockdown. Knockdown of CD9, CD151 and CD81 can be readily achieved using siRNA and/or small hairpin RNA (shRNA) 14, 146, 147 . This approach shows that endothelial cell CD9 and CD151 support lymphocyte transendothelial migration 146 , CD9 supports integrin-dependent adhesion and reduced dissemination in ovarian carcinoma cells 148 , and CD151 can regulate integrin-dependent cell adhesion and migration 147 . Additional RNAi studies show that osteoclastogenesis is inhibited by TSPAN13 but promoted by TSPAN5 (previously known as NET-4, TM4SF9) 149 . In infectious disease studies, silencing of CD81 with siRNA markedly inhibits (>90%) infection of primary normal human hepatocytes by HCv, much more effectively than soluble LEL from CD81 (ReF. 114) . Also, knockdown of CD151 significantly reduces susceptibility to porcine reproductive and respiratory syndrome virus infection in a model cell line 150 . The RNAi approach has already been used to inhibit tetraspanins in at least one in vivo study. Using an inducible shRNA vector, CD81 was targeted in rat brain, resulting in suppression of cocaine-induced locomotor activity 151 . The area of RNAi therapeutics is now sufficiently advanced, such that siRNAs can be made potent, specific (avoiding off-target effects) and chemically stabilized, although delivery to specific sites still needs to be optimized 152 . Regarding delivery, the recent use of specific mAbs to target siRNA-containing nanoparticles opens up a wide realm of new possibilities in which effects of relatively lethal siRNAs can be restricted to specific cell or tissue types 153 . with a number of different RNAi therapeutics already in clinical trials 152 , this technology should be available for application to tetraspanin targets.
Other possibilities. Tetraspanin transmembrane domains are involved in crucial intramolecular and intermolecular interactions that are essential for correct intramolecular folding and for intermolecular associations with other transmembrane proteins in TEMs 10, 89, 154, 155 . A study of G-protein-coupled receptors shows that structural analogues of individual transmembrane domains can serve as potent and specific receptor antagonists 156 . Hence, such an approach might also be applicable to tetraspanins. For example, transmembrane domain analogues that mimick single transmembrane domains in CD81 or CD151 conceivably could interfere with HCv infection or carcinoma progression, respectively.
The C-terminal cytoplasmic tail of tetraspanin CD63 interacts with a PDZ domain in Syntenin-1 to regulate CD63 endocytosis 157 . Several other tetraspanins also contain C-terminal three amino-acid sequences corresponding to potential PDZ domain binding motifs. PDZ domains, with their well-defined binding sites, are promising targets for drug discovery 158 . As additional tetraspanin-PDZ domain interactions are uncovered, prospects for PDZ intervention as a tetraspanin targeting strategy will be enhanced.
Other specific protein-protein interactions could also be targeted. The LELs of tetraspanins are being structurally characterized [7] [8] [9] , and key interaction sites are being mapped, such as between CD151 and integrins 137 . So, it should become more feasible to disrupt these interactions with small peptides or with other small molecules. In this regard, the interaction between CD81-soluble LEL has not yet been well documented. Also, they may sequester tetraspanins, leading to disruption of tetra spanin-enriched domains (TEMs), down-modulation or triggering of apoptosis. In addition, mAbs can be used to deliver a lethal hit to cells expressing particular tetraspanins. For example, the antibody might trigger apoptosis, complementdependent cytotoxicity or antibody-dependent cellular cytotoxicity, or deliver a conjugated toxin or lethal radioisotope or nanoparticle. b | Recombinant soluble large extracelullar loops (sLELs) most probably insert into TEMs, to disrupt lateral interactions among tetraspanins, or between tetraspanins and their partner molecules. In a special case, hepatitis C virus (HCV) infection, the CD81 sLEL acts in trans by binding to the virus and preventing interaction with cellular CD81. c | RNAi strategies are well documented to demonstrate the functional importance of tetraspanins. d | Other approaches might be useful for tetraspanin targeting. For example, a small molecule could be designed to inhibit the interaction of a C-terminal tail with a PDZ-domain protein. A peptide specifically mimicking a tetraspanin transmembrane domain might be effective in disrupting lateral interactions. Interference with the appropriate protein acyl transferase in the Golgi would prevent tetraspanin palmitoylation, leading to an inability to assemble TEMs and resulting in impaired functions.
DHHC2
A member of a family of enzymes (24 members in mammals) containing a conserved aspartate-histidinehistidine-cysteine (DHHC) motif, responsible for the S-palmitoylation of proteins.
and the HCv-E2 protein has been used to screen for small-molecule inhibitors, with the intention of blocking HCv infection 159, 160 . Palmitoylation of tetraspanins and partner proteins has a vital role during the assembly and/or maintenance of TEMs 10, [32] [33] [34] 43 . Palmitoylation of tetraspanin CD82 is particularly important for its association with HTLv-1 Gag protein, which may support virus assembly and release 120 . It is only recently that progress has been made in the identification of the protein acyl transferases that are responsible for protein palmitoylation 161 . Targeting relevant protein acyl transferases could provide a novel means of physically disrupting TEMs, thus leading to altered cell u lar functions. In this regard, a protein acyl transferase, called DHHC2, promotes tetraspanin palmitoylation while supporting TEM assembly 162 . It is not yet clear how to take advantage of tetraspanin tumour suppressor functions therapeutically. However, in the case of the metastasis suppressor CD82, an interesting new possibility has emerged. Because CD82 is degraded by gp78 ubiquitin ligase, targeting of gp78 increases abundance of CD82 while reducing metastasis 163 . whether other tetraspanin suppressors (for example, CD9, CD63 and TSPAN13) undergo post-translational downregulation that could be similarly targeted remains to be determined. Another possibility for amplifying tetraspanin suppression is through adenoviral transduction methods. Adenoviruses encoding CD9 or CD82 were administered, via the trachea, into mice orthotopically preimplanted with Lewis lung carcinoma cells, resulting in a dramatic reduction in metastasis 65 . Curiously, host-cell expression of CD9 itself may facilitate adeno-associated virus serotype 2 infection 164 . Despite their abundance in humans (33 tetraspanins), flies (36 tetraspanins), fish (66 tetraspanins), worms (21 tetraspanins) and elsewhere 1, 2 , and despite the large numbers of unbiased genetic screens that have been carried out, relatively few tetraspanins have been identified as having essential functions. Furthermore, knockout of individual tetraspanins in mice has resulted in relatively mild phenotypes. One reason for the lack of more dramatic phenotypes could be that there is substantial compensation by the remaining tetraspanins. Consequently, it is predicted that engineering dominant negative tetraspanins will yield phenotypic effects that exceed those of individual knockouts, and will more closely resemble the effects seen using mAbs and RNAi strategies in developed organisms.
Summary and future prospects So far, there have been few examples of tetraspanin targeting in vivo. Nonetheless, potential target opportunities abound as tetraspanins contribute to tumour progression, angiogenesis, fertilization, immune-cell functions, platelet clotting, infectious diseases and other processes. As more of the 33 mammalian tetraspanins are studied, and their functions and molecular interactions identified, the list of potential targets will grow as will possibilities for intervention.
Strategies for targeting tetraspanins include the use of mAbs and recombinant soluble LELs. The mAb and soluble LEL approaches can be complementary, as some processes are inhibited by one type of reagent but not the other. However, for both mAbs and soluble LELs, interpretation of results can be handicapped by not knowing the precise mechanism of action. It is often not clear which specific molecular interactions are being perturbed. Also, results can be a little unpredictable, as the same antibodies can stimulate or inhibit different types of cell fusion, and serve as both antagonists and agonists. The RNAi approach is clear in terms of mechanism and promising examples of both in vitro and in vivo applications have emerged.
The widespread distribution of many tetraspanins on numerous cell and tissue types is a potentially important obstacle to tetraspanin targeting. For example, agents that target CD9 on oocytes or CD151 on tumour cells might also affect the normal functions of platelets and endothelial cells, which also express abundant CD9 and CD151. Similarly, targeting of CD37 on B leukemic cells could also affect CD37-dependent functions of T cells. However, the development of cell-specific delivery systems may overcome this problem. Another issue is that of compensation and/or redundancy provided by non-targeted tetraspanins. To circumvent this, it may be necessary to focus on tetraspanins that have highly specific functions or to target multiple tetraspanins at once.
Finally, as tetraspanins function in the context of TEMs, a novel type of membrane microdomain, new strategies may need to be developed. For example, strategies aimed at non-protein elements in TEMs (such as gangliosides, cholesterol or palmitoylation), at specific transmembrane domain interactions, at specific cytoplasmic tail interactions, or at specific tetraspanin-partner combinations might be worth consideration.
